CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
CANADA

About Us

Conference

Partner With Us

  • APAC
    • US
    • EUROPE
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    Bioinformatics & Genomics
    BioTech
    Cell and Gene Therapy
    Drug Discovery and Development
    Life Science AI
    Next-Generation Sequencing
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    CDMO
    Cosmetic
    CRO
    Life Science Testing And Compliance
    Supplement Manufacturing
  • Business Services
    Life Science Consulting
    Life Sciences Marketing and Communication
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

UNC Health

Ashley L. Pappas, PharmD, MHA Director of Pharmacy Medication Management and Optimization | Pharmacy Analytics and Outcomes Pharmacy Services

Improving Drug Shortage Management

Ashley L. Pappas

Ashley L. Pappas

Drug shortages pose a serious and growing challenge to clinical practice and patient care. Over the past decade, the number of active and ongoing shortages that require management by health systems has increased. The inability to procure medications results in pharmacy departments having to identify alternative drug therapies, potentially resulting in delayed treatment and scenarios where front-line physicians are tasked with ordering unfamiliar medications, increasing the risk of medication errors. Moreover, in some care settings, like oncology, modifying a treatment regimen can negatively impact patient outcomes or treatment success.


There are a variety of contributing factors that can result in drug shortages. Common causes include quality issues with manufacturing plants, shortage of raw materials, supply and demand problems, or discontinuation of a product by a manufacturer, which is often driven by business decisions. Additionally, a lack of transparency in the supply chain can cause shortages regionally, which can cascade to a nationwide shortage. With any of these reasons, drug manufacturers are required to notify the FDA at least 6 months prior to discontinuing manufacturing of their drug product. 


Manufacturers are exempt from this requirement in circumstances where they are unable to provide advanced notification of a shortage, such as unexpected contamination of their production line. When there is no advanced notification to the FDA or the supply chain, health systems are forced to respond reactively.


"Over the past decade, the number of active and ongoing shortages that require management by health systems has increased"


While drug inventory management software programs are available, their focus is to support quick analysis of the supply chain in order to rapidly identify clinical alternatives for medications in short supply. One example of this technology is OrbitalRx, which collects data from disparate sources and aggregates it into a centralized platform. It provides insight into inventory levels and historical utilization. Once aggregated, the pharmacy team can streamline communication, decision making, and alternative medication procurement. Additionally, this platform has the potential to inform consumers if a shortage is unique to an institution or region. Although the available technology solutions support shortage management workflow, there is not yet a solution focused on predictive modeling of drug shortages.


The Tool


As predictive modeling has become more prevalent in sectors within and beyond healthcare, the UNC Health Department of Pharmacy has undertaken a project to develop a validated proactive drug inventory management model. At the onset of the COVID-19 pandemic, our team developed and validated a model to predict patient volumes and utilization of medications that were pertinent to COVID-19, as well as those with the highest odds of going on shortage.


While still in the early stages, we are applying a similar methodology in the development of a model intended to support proactive management of drug inventory in anticipation of drug shortages. This model will employ application of concepts such as odds ratio, medication utilization trends, and predicted patient volumes from the previous models outlined. The objective of this model is to utilize predictive analytics to proactively identify medications at high risk for supply disruption and subsequently mitigate risk to patient care, decrease waste, improve inventory management efficiency, and enhance our institution’s financial performance. We hope to establish a new precedence of drug shortage management through this project that can be expanded and shared with pharmacy departments throughout the nation.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review APAC
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review APAC. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreviewapac.com/leadership-perspective/improving-drug-shortage-management-nwid-743.html